Generic trademark

Epilepsy: Global Forecast & Market Analysis to 2035 - UCB Will Continue to Dominate the Epilepsy Market with Key Drugs Keppra & Vimpat - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 18, 2019
Health, Pharmaceutical, Drugs, Anticonvulsants, RTT, UCB, Levetiracetam, Epilepsy, Generic trademark

The "Epilepsy Forecast and Market Analysis to 2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Epilepsy Forecast and Market Analysis to 2035" report has been added to ResearchAndMarkets.com's offering.
  • Label expansions will drive uptake of newer brands, sustaining the epilepsy market by countering widespread genericization.
  • UCB will continue to dominate the epilepsy market with key drugs Keppra and Vimpat.
  • With positive Phase III data in LGS, Epidiolex is proving to be the therapy of choice for refractory childhood epilepsy.

Global Hyperlipidemia Drugs Market Analysis (2016-2022): AstraZeneca, Merck, Pfizer, Daiichi Sankyo, Amgen and Sanofi are Profiled

Retrieved on: 
Thursday, November 15, 2018
Lipid-lowering agent, Statin, Hyperlipidemia, Medicine, Cholesterol absorption inhibitor, Cholesterol, Generic trademark, Health, Clinical medicine

The global hyperlipidemia drugs market size is expected reach USD 22.6 billion by 2022, expanding at a CAGR of 2.3% during the forecast period.

Key Points: 
  • The global hyperlipidemia drugs market size is expected reach USD 22.6 billion by 2022, expanding at a CAGR of 2.3% during the forecast period.
  • Target population of antihyperlipidemic drugs is broadly divided into statin users and nonstatin users.
  • The nonstatin users segment consists of statin intolerant and nonresponsive population as well as familial hyperlipidemia (FH) population.
  • Upcoming patent expirations are expected to lead to greater genericization in the market, mostly among statins, cholesterol absorption inhibitors, and combination drugs.